Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Russo

Internal Medicine Youngstown, OH Medical Doctor

NPI 1366890410 CMS profile 5697929

500 Gypsy Lane, Youngstown, OH 44501

Open in the dashboard

General payments

$8,459

536 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anthony Russo of Youngstown, OH is reported in the CMS Open Payments database as having received $8,459 across 536 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $184 10
2024 General $2,149 136
2023 General $2,142 125
2022 General $1,870 114
2021 General $964 67
2020 General $779 64
2019 General $370 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Russo
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Anthony Russo were reported at $184. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Anthony Russo Internal Medicine median Middle half National median
2019 $370 $159 $48–$570 $163
2020 $779 $119 $33–$402 $114
2021 $964 $135 $37–$521 $132
2022 $1,870 $141 $42–$496 $149
2023 $2,142 $149 $45–$519 $160
2024 $2,149 $154 $47–$537 $164
2025 $184 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,545 94 payments
  2. Novo Nordisk Inc $834 63 payments
  3. AstraZeneca Pharmaceuticals LP $732 32 payments
  4. Lilly USA, LLC $647 43 payments
  5. Pfizer Inc. $625 55 payments
  6. Astellas Pharma US Inc $446 18 payments
  7. Amarin Pharma Inc. $421 37 payments
  8. Amgen Inc. $386 26 payments
  9. Merck Sharp & Dohme Corporation $371 25 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $345 25 payments
  11. Other $2,107 118 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,233 533 payments
  2. Education $226 3 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $758 44 payments
  2. Ozempic $520 37 payments
  3. RYBELSUS $505 36 payments
  4. FARXIGA $466 16 payments
  5. MOUNJARO $435 25 payments
  6. QULIPTA $428 28 payments
  7. Vascepa $394 35 payments
  8. NURTEC ODT $385 36 payments
  9. Repatha $348 24 payments
  10. VRAYLAR $325 20 payments
  11. Other $7,099 454 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 140 drugs

Part D claims

8,488

Median for Internal Medicine: 777

Drug cost

$815,958

Median for Internal Medicine: $73,373

Branded share of claims

19.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 200 $218,126
Ozempic Semaglutide Brand 81 $134,517
Mounjaro Tirzepatide Brand 35 $54,994
Jardiance Empagliflozin Brand 46 $52,018
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 49 $46,490
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 64 $42,207
Entresto Sacubitril/Valsartan Brand 44 $37,769
Januvia Sitagliptin Phosphate Brand 23 $34,649
Xarelto Rivaroxaban Brand 38 $28,565
Myrbetriq Mirabegron Brand 40 $28,239

The 10 drugs with the highest cost, of 140 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$68,050

Of which drugs: $688

Medicare patients

296

Average age 77

Services billed

944

149 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Ischemic heart disease 40%
Diabetes 38%
Heart failure 35%
Chronic kidney disease 35%
Atrial fibrillation 31%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $181
$181 — —
UBRELVY
  • AbbVie, Inc. $172
$172 — —
Veozah
  • Astellas Pharma US Inc $138
$138 — —
MOUNJARO
  • Lilly USA, LLC $124
$124 35 —
NURTEC ODT
  • PFIZER INC. $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

536 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record